CCC. Copie-Bergman

C. Copie-Bergman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


C. Copie-Bergman has a total of 56 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Phase I/II study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered weekly to patients (pts) with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL).

    by B. Coiffier, V. Ribrag, J. Dupuis, H. Tilly, C. Haioun, F. Morschhauser, T. Lamy, C. Copie-Bergman, O. Brehar, R. Houot, et al.

    8017 Background: SAR3419 (huB4-DM4) is an antibody–drug conjugate composed of a humanized IgG1 monoclonal antibody, huB4, which specifically targets the CD19 antigen, conjugated through a disulfide link to the maytansinoid derivative DM4, a potent tubulin inhibitor. After binding to the CD19 antigen, SAR3419 undergoes internalization and intracellular release of DM4. Methods: In this phase I/II study SAR3419 was administered by intravenous infusion, weekly for 8 to 12 doses, to pts with relapsed/refractory B-cell NHL expressing CD19. Results: Forty-four pts were enrolled at 7 dose levels from 10 to 70 mg/m². Main histologies were follicular (18; 41%) and diffuse large B-cell (17; 39%). Median number of prior regimens was 3 (1-8) and 19 pts had received prior transplantation. Twenty-eight pts were enrolled in the dose escalation part. Of 6 pts at 70 mg/m², 1 pt had a protocol defined dose limiting toxicity of neutropenia and 2 pts had grade 2 significant toxicities with late onset: blurred vision associated with corneal deposits and left bundle branch block. The maximum tolerated dose (MTD) was defined at 55 mg/m². Of 22 pts at the MTD, 4 pts had related reversible grade 3-4 toxicities after 6-8 doses: optic neuropathy, paraesthesia, neutropenia and thrombocytopenia. Of 38 pts at doses of 20 mg/m² or higher, 12 (32%) pts achieved an objective response including 6 CR/CRu, with no obvious dose effect. Of 22 pts at the MTD (55 mg/m²), 8 (36%) had a response, including 3 CR/CRu. Of 9 pts evaluable for response duration (RD), 4 pts had a RD ranging from 6 to at least 12 months. Conclusions: These results demonstrate evidence of clinical activity and manageable safety, without significant myelosuppression. A modified schedule (4 weekly doses of 55 mg/m² followed by every 2 weeks dosing) is under evaluation. Updated clinical and pharmacokinetic data will be presented.


  • Clinical relevance of a positive result in cerebrospinal fluid (CSF) by flow cytometry (FCM) in patients with diffuse large B-cell lymphoma (DLBCL).

    by R. Alvarez, J. Dupuis, A. Plonquet, C. Christov, C. Copie-Bergman, I. Gaillard, T. EL Gnaoui, K. Belhadj, F. Hemery, C. Haioun

    8089 Background: Central nervous system (CNS) relapse is an uncommon but serious complication of non-Hodgkin lymphoma and usually occurs early in the disease course, suggesting subclinical disease at diagnosis. Several studies have demonstrated the superiority of FCM analysis of CSF, as compared to conventional cytology (CC), in detecting occult leptomeningeal disease in heterogeneous groups of aggressive lymphoma. Nevertheless, the clinical relevance of a positive FCM is still to be determined in DLBCL. Methods: We reviewed CSF samples from 114 patients (pts) with DLBCL (15% being transformed follicular lymphoma), analyzed both by FCM and CC, between 2005 and 2009. Ninety-three samples were from newly diagnosed (ND) pts and 21 from pts in relapse. The R-IPI in ND was very good (2%), good (42%) and poor (56%). First-line treatments included R-CHOP (n=81) and R- ACVBP (n=9) regimens with methotrexate intrathecal prophylaxis, and pts in relapse received several types of salvage treatments. A FCM+ did not influence treatment strategies. Results: Seventeen samples of the 114 were FCM+, versus 1 sample CC+ (this being also FCM+). In order not to overestimate the risk of CNS relapse, we excluded from the analysis pts with signs at presentation suggesting leptomeningeal disease (n=13). Therefore, within ND pts without neurological signs (n=86), 9 (10%) were FCM+, versus 4 FCM+ (27%) in the 15 pts in relapse. In the first group, 1/9 (11%) developed CNS relapse versus 0/4 (0%) in the second group. Within all pts without neurological signs (n=101), 4 (4%) relapsed in the CNS, with a median time to relapse of 5.2 months. In those, only 1/4 (25%) was FCM+ prior to relapse. Clinical features that showed an association with CNS relapse were: more than one extranodal site (ENS) of disease and the conjunction of elevated LDH and ENS>1 (p=0.04 and p=0.018, respectively). Conclusions: FCM gives far more positive results than CC, when analyzing CSF of pts with DLBCL (17/114 FCM+, versus 1/114 CC+). However, a positive FCM result did not translate into an increased relapse rate in the CNS, in this population. Therefore, FCM failed to have a predictive value in the occurrence of CNS relapse in DLBCL. No significant financial relationships to disclose.

  • Lymphome du MALT thymique dans un contexte dysimmunitaire de type Sjögren avec transformation en lymphome B de haut grade

    by J. Moroch, M. Dachert, J. Dugay, C. Copie-Bergman, V. Frenkel, P. Gaulard, A. Foulet-Roge

  • Open Access

    Metachronous gastric MALT lymphoma and early gastric cancer: is residual lymphoma a risk factor for the development of gastric carcinoma?

    by C. Copie-Bergman, C. Locher, M. Levy, M. T. Chaumette, C. Haioun, M. H. Delfau-Larue, K. Leroy, P. Gaulard, J. C. Delchier

    Background: Helicobacter pylori plays a major role in the pathogenesis of primary gastric MALT lymphoma (GML) and gastric carcinoma. The occurrence of these two diseases metachronously in a same patient is a rare event. Patients and methods: Gastric biopsies and gastrectomy resection specimens of four patients who developed GML and early gastric cancer (EGC) were analysed by morphology, immunohistochemistry and molecular biology. Results: Four patients (three males and one female; mean age 48 years) were diagnosed with GML. Helicobacter pylori infection was observed in three cases. Two patients had localized disease (stages IE and IIE, respectively) and were treated with H. pylori eradication therapy followed by an alkylating agent for one patient. Two patients had disseminated disease (stage IV), and were treated with an alkylating agent. Three cases were t(11;18) positive. All patients achieved initially complete lymphoma remission. Long-term endoscopic surveillance detected an EGC at the same location as the lymphoma in all patients at a mean time of 9.5 years (range 2.5–17 years) after lymphoma diagnosis. Gastrectomy specimens showed residual GML in all cases. Conclusion: Prolonged residual GML could constitute an additional risk factor for the development of gastric carcinoma. Long-term endoscopic surveillance is mandatory in patients treated conservatively for gastric MALT lymphoma.


  • Rituximab, gemcitabine and oxaliplatin (R-GEMOX): A promising regimen for refractory/relapsed B-cell lymphoma

    by T. El Gnaoui, B. Joly, J. Dupuis, K. Belhadj, A. Rahmouni, C. Copie-Bergman, A. Allain, I. Tabah-Fisch, F. Reyes, C. Haioun

    6592 Background: High-dose therapy with autologous stem cell support (HDT) is now an established treatment for chemosensitive relapse in aggressive lymphoma. However, not all patients are candidates for HDT because of age, comorbidities or previous HDT. Effective and well-tolerated salvage therapies with minimal toxicities are needed. Methods: We designed the R-GEMOX regimen, with rituximab 375mg/m2 d1, gemcitabine 1000 mg/m2 d2 and oxaliplatin 100 mg/m2 d2 (recycling on d15). Between January 2002 and August 2003, 24 patients with refractory/relapsing B-cell lymphoma not eligible for HDT were enrolled in an open unicenter pilot study whose primary objective was to determine the overall response rate (ORR) after 4 cycles of R-GEMOX. Patients were planned to receive 8 cycles if a good response (at least PR) was observed after 4 cycles. Median age was 64 years (range: 43–77) and histological subtypes were : diffuse large B-cell lymphoma (n=16), follicular (n=6) and mantle cell (n=2). Prior treatment included anthracyclin (n=22), rituximab (n=11) and HDT (n=6). The median number of prior treatments was 2 (range : 1 to 5) and 8 patients had received at least 3 prior regimens. Results: 172 cycles were given. The dose administered was 100% of the intended dose for the three drugs in all patients but 4, for whom the dose of oxaliplatin was reduced due to neurotoxicity (n=3) or preexisting renal insufficiency (n=1). Two patients progressed after 3 cycles. After 4 cycles, observed responses were: 6 CR, 4 CRu, 11 PR and 1 failure resulting in an ORR of 88 %. Among the 21 responders after 4 cycles, 17 achieved CR or CRu, 2 remained in PR after completion of 8 cycles. Treatment was stopped after 5 cycles in 2 patients because of physician decision. As of December 2003, 22 patients are alive, 15 in continuous complete remission, 3 in CRu, 2 in PR and 2 in progression. NCIC grade 3–4 neutropenia and thrombocytopenia were reported in 50% and 21% of cycles. Two patients developed a grade 4 infection. There was no renal toxicity. Conclusion: The R-GEMOX regimen shows promising activity with an acceptable toxicity. It is evaluated in an ongoing multicentric phase II study.

  • Open Access

    Proposal for a new histological grading system for post-treatment evaluation of gastric MALT lymphoma

    by C Copie-Bergman, P Gaulard, A Lavergne-Slove, N Brousse, J F Fléjou, K Dordonne, A de Mascarel, A C Wotherspoon


    • 1 March 1998
      • Vol. 91  (5) , 1723-31

    Nonhepatosplenic gammadelta T-cell lymphoma: a subset of cytotoxic lymphomas with mucosal or skin localization.

    by B Arnulf, C Copie-Bergman, M H Delfau-Larue, A Lavergne-Slove, J Bosq, J Wechsler, M Wassef, C Matuchansky, B Epardeau, M Stern, et al.

    Human gammadelta T lymphocytes represent a minor subset of T cells in the peripheral blood, which exhibit a limited diversity and a tissue-restricted repertoire in contrast to their broad specificity. Most postthymic neoplasms that arise from this T-cell subpopulation belong to the hepatosplenic gammadelta lymphoma entity. Only a few cases of nonhepatosplenic gammadelta lymphomas have been described in detail previously. This study presents the clinicopathologic features of 11 consecutive cases of nonhepatosplenic gammadelta lymphoma. All were characterized by mucosal or skin initial involvement: nasal cavity (n = 3), gastrointestinal tract (n = 3), skin (n = 3), lung (n = 1), larynx (n = 1). Most patients presented with B symptoms (eight of 11), without peripheral lymphadenopathy and bone marrow involvement. A past history of chronic antigen exposure was noted in six cases, and four patients had features of immune deficiency. On histology, they were classified as pleomorphic tumors. Features of epitheliotropism and angiocentrism was observed in most cases. Tumor cells had a CD2+, CD3+, T-cell receptor (TCR)delta-1+), betaF1- phenotype. They were CD5- (9 of 10) and CD4-/CD8- (9 of 10) or CD8+ (1 of 10). A clonal gamma-chain gene rearrangement was detected in all tested cases (9/9). All cases had an activated cytotoxic T-cell intracellular antigen-1 (TIA-1)+, Granzyme B+ phenotype. Epstein-Barr virus (EBV) sequences were detected in six cases by in situ hybridization (ISH). Despite an aggressive clinical course, complete remission was obtained in three patients, and one of the latter required a peripheral blood stem-cell transplantation. Nonhepatosplenic gammadelta peripheral T-cell lymphoma can be regarded as a model of activated cytotoxic lymphoma, occurring in mucosae or skin. These appear to be derived from the subpopulation of tissue-restricted gammadelta lymphocytes, which are involved in the host epithelial surface surveillance. The role of chronic antigen exposure in the pathogenesis of these rare lymphomas can be suggested, in view of the past history observed in at least some patients.